

Resource Summary Report

Generated by RRID on Aug 7, 2026

MOB1 (E1N9D)

RRID:AB_2783010

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 13730, RRID:AB_2783010

Antibody Information

URL: http://antibodyregistry.org/AB_2783010

Proper Citation: Cell Signaling Technology Cat# 13730, RRID:AB_2783010

Target Antigen: MOB1

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: W, IP

Antibody Name: MOB1 (E1N9D)

Description: This monoclonal targets MOB1

Target Organism: monkey, rat, hamster, mouse, human

Clone ID: E1N9D

Antibody ID: AB_2783010

Vendor: Cell Signaling Technology

Catalog Number: 13730

Record Creation Time: 20250820T030414+0000

Record Last Update: 20250820T151625+0000

Ratings and Alerts

No rating or validation information has been found for MOB1 (E1N9D).

No alerts have been found for MOB1 (E1N9D).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Potter R, et al. (2026) The serotonin receptor 2b (5-HT2B) modulates heart remodeling following myocardial infarction via regulation of Hippo pathway. *iScience*, 29(2), 114825.

Li L, et al. (2026) USP25 aggravates liver cancer development and impairs chemosensitivity by limiting LATS1 activation. *EMBO reports*, 27(9), 2406.

Shi Y, et al. (2025) Piezo1 senses hyphae and initiates host defense against pathogenic fungi. *Cell reports*, 44(6), 115839.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. *Cancer research*, 85(4), 660.

Qi S, et al. (2023) Two Hippo signaling modules orchestrate liver size and tumorigenesis. *The EMBO journal*, e112126.

Lin TY, et al. (2023) Epinephrine inhibits PI3K? via the Hippo kinases. *Cell reports*, 42(12), 113535.

Zhang H, et al. (2023) MAP4Ks inhibition promotes retinal neuron regeneration from Müller glia in adult mice. *NPJ Regenerative medicine*, 8(1), 36.

Qi S, et al. (2022) WWC proteins mediate LATS1/2 activation by Hippo kinases and imply a tumor suppression strategy. *Molecular cell*, 82(10), 1850.

Wang Y, et al. (2021) Stabilization of Motin family proteins in NF2-deficient cells prevents full activation of YAP/TAZ and rapid tumorigenesis. *Cell reports*, 36(8), 109596.

Liu Q, et al. (2021) Glycogen accumulation and phase separation drives liver tumor initiation. *Cell*, 184(22), 5559.

Chen Z, et al. (2020) Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling. *JCI insight*, 5(20).

Tang Y, et al. (2020) Selective Inhibition of STRN3-Containing PP2A Phosphatase Restores Hippo Tumor-Suppressor Activity in Gastric Cancer. *Cancer cell*, 38(1), 115.

He L, et al. (2020) A Regulation Loop between YAP and NR4A1 Balances Cell Proliferation and Apoptosis. *Cell reports*, 33(3), 108284.

Song J, et al. (2019) Kindlin-2 Inhibits the Hippo Signaling Pathway by Promoting Degradation of MOB1. *Cell reports*, 29(11), 3664.

Triastuti E, et al. (2019) Pharmacological inhibition of Hippo pathway, with the novel kinase inhibitor XMU-MP-1, protects the heart against adverse effects during pressure overload. *British journal of pharmacology*, 176(20), 3956.